Icsori

Fluticasone Propionate, the active ingredient in Icsori, is a corticosteroid presented as an inhalation product for inhalation use. It reduces airway inflammation and hyper‑responsiveness in patients with asthma and chronic obstructive pulmonary disease (COPD). It is used as maintenance therapy to improve lung function, lower the frequency of exacerbations, and enhance quality of life for individuals with these chronic respiratory diseases.

GNH USA supplies Icsori as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide, ensuring quality assurance and regulatory compliance across diverse markets.

Fluticasone Propionate is an inhaled glucocorticoid used to manage inflammatory airway diseases.

- Asthma: decreases airway inflammation, improves symptom control and reduces the risk of severe attacks. - Chronic obstructive pulmonary disease (COPD): lowers inflammation, enhances lung function and helps prevent exacerbations. - Maintenance therapy for chronic respiratory disease: provides long‑term anti‑inflammatory effect to sustain airway patency.

Fluticasone Propionate may be associated with a range of adverse reactions, most of which are related to its local corticosteroid activity in the airways.

Common Side Effects: - Oral thrush (candidiasis): fungal infection of the mouth. - Hoarseness or voice changes: irritation of the vocal cords. - Cough or throat irritation: local discomfort after inhalation.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Adrenal suppression: reduced endogenous cortisol production. - Severe hypersensitivity reactions: anaphylaxis or angioedema.

When prescribing Fluticasone Propionate inhalation, clinicians should consider several precautionary measures to ensure safe use. - Assess infection risk: avoid use during active respiratory infections unless benefits outweigh risks. - Monitor growth in children: prolonged therapy may affect growth velocity. - Evaluate bone health: consider calcium/vitamin D supplementation for long‑term users. - Use proper inhalation technique: educate patients to rinse mouth after each dose to reduce local effects. - Review concomitant medications: be cautious with other systemic corticosteroids. - Store at room temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Fluticasone Propionate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure and risk of adrenal suppression. - Systemic corticosteroids: additive glucocorticoid effects can enhance immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce fluticasone levels and diminish therapeutic effect. - Anticholinergic bronchodilators: may mask bronchospasm symptoms. - Diuretics: potential for electrolyte imbalance if systemic absorption occurs.